Sarepta Dives Deeper into Gene Therapy (PharmaPhorum)

Sarepta Therapeutics has handed $30 million to UF startup and Sid Martin Biotech resident client Lacerta in exchange for a group of gene therapies, including a Pompe disease candidate.

According to the agreement Sarepta will make an equity investment of $30 million in Lacerta Therapeutics gaining rights to two unnamed CNS-targeted gene therapy programs including exclusive rights to Pompe disease therapy.

The deal has been announced during Sarepta’s Q2 call praising “better-than-expected results” and the robust sales of its EXONDYS 51 treatment developed for Duchenne muscular dystrophy patients.

Learn more about Sarepta Dives Deeper into Gene Therapy.